Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Updates from the Phase II AERN trial: nivolumab and radiotherapy for the treatment of R/R HL

Paul Jan Bröckelmann • 10 Jun 2022
EHA 2022
Hodgkin Lymphoma Lymphoma Antibodies Nivolumab
AERN

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, shares some updates from the Phase II AERN trial (NCT03480334) evaluating the use of nivolumab and radiotherapy for the treatment of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who have failed prior anti-PD1 treatment. Dr Bröckelmann highlights some results from this trial, drawing focus on the abscopal effect of this treatment approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Paul Jan Bröckelmann

2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals